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SUMMARY
This paper provides local data on the provision of services for patients diagnosed with ovarian
cancer in 1996 prior to the reorganisation of cancer services. It documents a service for 140
patients provided by 80 consultant teams and illustrates the need for reorganisation to meet the
evidence base already in existence for improvement in survival and will serve as a baseline for
future audits in this area.
INTRODUCTION
Driven by some of the worst survival rates in
Western Europe' there has been widespread
reorganisation in recent years of the way cancer
services in the UK are delivered.2 Given the need
to improve service quality and to justify the
massive resource commitment required,
monitoringandevaluationofthechangesinterms
of care processes and outcomes are clearly
required.Thesemaybemeasuredusingthepatient
carepathway. Wereporthereanexamplerelating
to ovarian cancer.
In 1996theCampbellreport3madewide-ranging
recommendations for change in the way cancer
services were organised in Northern Ireland.
Broadly in line with those made by the Calman
Hine report for the NHS in England and Wales,2
theyincludedcentralising careforthe 1.7 million
population within 5 cancer units and 1 cancer
centre, providing care by designated specialists
workinginmultidisciplinaryteamsandenhancing
communication between primary and secondary
care.
Recommendations specifictoovariancancerwere
the use ofultrasound scanning and measurement
of blood tumour marker levels as part of the
assessment process, and the development of
regionally agreed management guidelines to be
used within anetworkofcare. Thelatestregional
guidance determines that treatment should only
take place in the cancer centre or in a cancer unit
and only under the care of a lead clinician in
gynaecologicaloncology.Iftreatmentisproposed
to take place in a cancer unit the patient's
management plan should be agreed with the
multidisciplinary team at the cancer centre.4
Observational studies of patients with ovarian
cancer lend broad support to these
recommendations. The involvement of a
gynaecologistatbothpresentationandtreatment,
and further management by a multidisciplinary
team have been shown to improve survival.5 6'7
Operation by specialist gynaecologists has also
been found to improve survival among women
with stage III disease.8 However, the case for
ensuring operators treat an optimum volume of
patients is unproven to date.7
Partofalargerstudy oftheoverallcancerservice
changes in Northern Ireland, this paper aims to
provideabaselinedescriptionofthecarereceived
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bywomendiagnosedin 1996withovariancancer,
prior to anticipated service change.
METHODS
All ovarian cancer notifications for 1996 were
extracted from the Northern Ireland Cancer
Registry. This included both fully malignant and
borderlinemalignanttumours,inaccordancewith
the ICD-0-2 classification.9
Aretrospectivereviewofrecordswasundertaken
by one trained researcher (RM). For inclusion in
the study each case was required to have at least
oneofthefollowing: hospitalcasenotes; General
Practitioner records or histopathology reports.
Inadditiontothebasicdemographicinformation,
details ofpresenting symptoms, the referral and
assessment processes, diagnostic procedures,
tumour information, treatment details, and
outcomes were collected.
Information was recorded on aMicrosoft Access
database and analysed using SPSS software.
Follow-up of patients was carried out up to 31
December 1999. Cox's proportional hazards
regression model was fitted to the data, in order
to investigate ifage at diagnosis (under and over
65 years), stage of disease and treatment were
significant predictors of survival.
RESULTS
144 incident cases of ovarian cancer and
borderline malignancy were reported to the
NorthernIrelandCancerRegistry. Threecasesof
serous cystadenomas wrongly registered as
"serous cystadenocarcinomas" and one case of
pseudomyxoma peritonei were found on
examination ofnotes; these cases were excluded
fromthestudy. 137(97.9%)casesmetourcriteria
for inclusion in the study. Forfour ofthese, only
histopathology records were available.
Patient/disease characteristics
The mean age ofthepatients was 62 years (range
15 to 91, median 63). Surgical FIGO staging was
recorded in the notes of only 69 (55.2%) cases.
However,usingthevariousdatasourcesavailable
it was possible for the researcher to stage 119
patients. Using the FIGO system 15 (12.6%) had
borderline malignancy, 29 (24.4%) were stage I,
12 (10.1%) were stage II, and 63 (52.9%%) were
stage III or IV.
Referral
The source of referral was available for 110
cases. 90 (81.8%) cases were referred by their
GP. 56 (50%) cases were seen as an outpatient
referral, with 49 (43.7%) as emergency
admissions. Based on 108 cases, 58% ofpatients
were seen the same day as referral, with 75%
within 10 days of referral (range 0-164).
Assessment
Details of presenting symptoms were available
for 1 7 patients. Abdominalpain75 (64.1%) and
abdominal distension 44 (37.6%) were the most
common presenting symptoms. Others included
weight loss 22 (18.8%), dyspepsia 18 (15.4%),
urinary frequency 11 (9.4%), anorexia 5 (4.3%),
altered bowel habit 5 (4.3%), and weight gain 4
(3.4%). Nine (7.7%) cases were asymptomatic at
presentation. The median duration ofabdominal
pain at presentation to hospital was two months
(range one week to two years).
Patients presented to 80 different consultant
teams, 56 ofwhom assessed only one case each.
The largest caseload at presentation was five
patients. 16 cases were unattributable to a
particular team. Initial assessment was by
obstetricians or gynaecologists in 67 (55.4%)
cases,general surgeonsin27(22.3%),physicians
in 21 (17.4%), and urologists in two (1.5%)
cases. However, in 109 (79.6%) patients a
gynaecological opinion was received, while in
eight (5.8%) cases this was not sought. For 20
(14.6%) patients these details are unknown.
Detailsofpre-surgicalassessmentwereavailable
for 115 patients. Investigations included CA 125
in59(43%) cases, ultrasound scan96(70%), and
CT scan in 35 (25.5%). 46 (40%) patients had
both CA125 and ultrasound scan including
transvaginal ultrasound performed.
Based on an analysis of 115 cases the median
time from first hospital visit to diagnosis was 13
days, 70% were diagnosed within 33 days and
90% of within 108 days (range 0-399).
Surgical treatment
114 (83.2%) patients underwent some form of
surgical procedure (see Table 1). In four cases
this was limited to pleural tap or paracentesis.
The type of surgical procedure varied across the
stages of disease. Table 2 gives details for cases
wherestagewasderivedbyexaminationofnotes.
Operator details
65 different clinicians operated on thesepatients
with 43 operating on only one case each. Four
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TABLE I
Procedures by FIGO Stage ofDisease
Stage Pleural tap! Biopsy! SOIBSO SOIBSO/ TAHI TAHI Other
paracentesis laparotomy OM BSO BSO/
OM
Borderline 0 0 9 1 4 1
Other
Stage I 0 0 8 3 15 3
Stage II 1 0 3 2 2 3
Stage III 1 4 6 11 13 6
Stage IV 2 1 1 3 0 0 3
Unknown 0 1 0 0 5 0 2
Total 4 6 27 20 39 13 5
= Salpingo Oophorectomy
= Bilateral S 0
= Omentectomy
= Total Abdominal Hysterectomy
= 11 patients
clinicians operated on five or more, with the
highest caseload being nine. Operations took
place at21 differenthospitalsites acrossNorthern
Ireland.
Based on data for 99 cases, obstetricians or
gynaecologists operated on 79 (79.8%). This
includes three clinicians with specialist
gynaecological oncology training who operated
on20(20.2%)patients. General surgeonsoperated
on 17 (17.2%), including fourpatients with stage
I disease.
Adjuvant treatment
75 (54.7%) cases were discussed with an
oncologist, while 22 (16%) were recorded as not
discussed. In 40 (29.2%) cases this was not
recorded or notes were unavailable. Although
eight oncologists were involved, 58 of the cases
were discussed with one oncologist who
specialises in the treatment of gynaecological
cancer. The median time from referral to being
seen by an oncologist was one day (range 0-32).
75 (54.7%) patients had chemotherapy, eight
(10.6%) did not, andin54(39.4%) cases this was
notrecorded ornotes wereunavailable. 23(30.7%)
patients wereofferedentry into aclinical trial: 18
(24%) accepted. Based on 69 case notes the
median time from diagnosis to receipt of
chemotherapy was 28 days (range 0-138).
Communication
In 63 (46%) cases, the diagnosis was discussed
with the patient and in four (2.9%) the diagnosis
was recorded as not discussed. For 70 (51.1%)
this was not recorded or notes were unavailable.
There was evidence of a letter to the patient's GP
in 114 (83%) cases. The prognosis was recorded
in 53 (46.5%) of these. In 45 (39.5%) the letter
recorded that the diagnosis was discussed with
the patient.
Status at 30 days post operatively
After 30 days, 100 (88.0%) cases were alive,
eight (7.0%) were deceased and the status of six
(5.0%) was unknown for this period.
Survival
Whether a patient received radiotherapy and/or
chemotherapy did not have a significant effect
(P>0.05) on the hazard of ovarian cancer death;
however the numbers of patients involved are
small. Only the stage of disease was found to be
a significant predictor of the risk of death from
ovarian cancer(P<0.05).Foreachstageofdisease,
the hazard for ovarian cancer death was higher
The Ulster Medical Society, 2003.
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TABLE II
Relative survival ratesfor ovarian cancerpatients N.L 1996 by stage ofdisease
Year Borderline Stage 1 Stage 2 Stage 3 Stage 4 All Stages
0-1 100 90 93 66 48 77
1-2 100 84 69 35 - 58
2-3 100 71 - 23 - 46
3-4 100 72 - 15 - 44
- Denotes intervals with unstable survival estimates due to too few individuals.
than the hazard of borderline ovarian cancer
death. Therelative survivalratesforeachstageof
disease are given in Table II and Figure.
DISCUSSION
Against a background of the introduction of
evidence-based recommendations forchanges in
cancerserviceprovisioninNorthernIreland, this
study aimed to provide a baseline picture of the
process of care and patient outcome for ovarian
cancer prior to service reorganisation.
Service organisation
A large number of clinicians from different
specialisms working in many different hospital
sites were involved in diagnosing and treating
women with ovarian cancer in Northern Ireland
in 1996. Consequentlythemajorityofindividuals
ortheirteams lookedafteronly one such case per
year. Similar patterns have been reported by
auditsconductedinEnglandin 199110and 1996.11
While 80% ofwomen received a gynaecological
opinion during the process at least 5.8% (and
possibly up to 20%) ofcases did not, this despite
published evidence of the benefit of such a
consultation.5,6,8
Care processes
Variations in surgical practice exist although we
must be careful in further interpretation, as the
totalinformationwhichcouldinfluencetreatment
including patient views were not available to us.
While only 11.4% of women received the
currently advocated surgical treatment of TAH/
BSO/Omentectomy, this might be confounded
by technical difficulties in advanced disease, by
previous gynaecological surgery, or by younger
women wishing to preserve their fertility.
Omentectomy when considered in Borderline/
StageIdiseaseisnotsubjecttotheseconfounders
and may be a better marker of appropriateness.
FIGURE
Ovarian Survival by Stage ofDisease
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This however was a component of treatment in
onlyeight(18.2%) suchcases,raisingthepotential
forunderstagingandundertreatmentofdisease.10
Again, audits elsewhere have emphasised the
variation in surgical practice and shown similar
resultsforcaseswithdiseasestagingrecorded,101 I
and the percentage receiving chemotherapy.'2
Poor availability of routine stage information at
the time of diagnosis will result in problems
interpreting reasons for change in survival
overtime.
Communication
These results focus attention on communication
at the hospital/primary care interface. While a
lettertothepatient'sGPwasfoundinthemajority
of cases, only a minority included whether the
diagnosis or prognosis had been discussed with
thepatient. TheCampbellreport IiSexplicitinits
recognitionofthecentralroleofprimary careand
its need for "timely and appropriate
communication with the hospital sector".
Fourpatients had a written record indicating that
non-discussion of their diagnosis was an active
© The Ulster Medical Society, 2003.
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part of their management. This has implications
for the acquisition ofinformed consent, an issue
currently underdiscussion inrelation toresearch
in general.
Study methodology
This work was carried out in a population-based
cancer registry. Cancer registries are ideally
placed to assist in the key public health function
of service evaluation. Working in established
partnerships with numerous reporting agencies
theyhaveconsiderableexpertiseinthecollection,
collation, analysis and dissemination of
population-based data within a data protection
framework.
The main limitation of the study lies in the fact
that it was carried out some three to four years
after the majority of patient treatment had
occurred. Underreporting ofthe true picture can
be a problem in any retrospective study, but is
compounded in this case by our inability to
differentiate between data genuinely "not
recorded"andthatmissingbecauseofunavailable
casenotes, aswedidnotrecordwhichdatasources
were accessed for each case. In addition, there is
theimpressionthatnotestendedtobeunavailable
for deceased patients as opposed to survivors.
This missing data may therefore be more
representative of women with advanced disease
at presentation.
CONCLUSION
This population-based study documents both the
process and outcomes of care for women
diagnosedwithovariancancerinNorthernIreland
in 1996. Thefindings suggest apicture ofservice
provision very different from that later
recommendedbytheCampbellReport,yetsimilar
to that seen elsewhere in the UK at that time. A
study ofcases incident in 2001 is now underway
to close the audit loop.
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